ECSP099735A - Polipeptidos de factor vii modificados y usos de los mismos - Google Patents

Polipeptidos de factor vii modificados y usos de los mismos

Info

Publication number
ECSP099735A
ECSP099735A EC2009009735A ECSP099735A ECSP099735A EC SP099735 A ECSP099735 A EC SP099735A EC 2009009735 A EC2009009735 A EC 2009009735A EC SP099735 A ECSP099735 A EC SP099735A EC SP099735 A ECSP099735 A EC SP099735A
Authority
EC
Ecuador
Prior art keywords
factor vii
polipeptides
same
modified
modified factor
Prior art date
Application number
EC2009009735A
Other languages
English (en)
Inventor
Edwin L Madison
Christopher D Thanos
Sandra Waugh Ruggles
Shaun Coughlin
Original Assignee
Catalyst Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalyst Biosciences Inc filed Critical Catalyst Biosciences Inc
Publication of ECSP099735A publication Critical patent/ECSP099735A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

Se suministran polipéptidos de factor VII modificados y usos de los mismos. Dichos polipéptidos FVII modificados incluyen Factor VIIa y otras formas del Factor VII. Entre los polipéptidos FVII suministrados se encuentran aquellos que tienen actividades alteradas, típicamente actividad procoagulante alterada, incluyendo actividades procoagulante aumentadas. Así, dichos polipéptidos modificados son terapéuticos.
EC2009009735A 2007-04-13 2009-11-13 Polipeptidos de factor vii modificados y usos de los mismos ECSP099735A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92351207P 2007-04-13 2007-04-13

Publications (1)

Publication Number Publication Date
ECSP099735A true ECSP099735A (es) 2010-01-29

Family

ID=39689319

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009735A ECSP099735A (es) 2007-04-13 2009-11-13 Polipeptidos de factor vii modificados y usos de los mismos

Country Status (29)

Country Link
US (1) US20100166729A9 (es)
EP (2) EP2147096B1 (es)
JP (3) JP5761782B2 (es)
KR (2) KR20100016462A (es)
CN (2) CN101743309B (es)
AU (1) AU2008239586B2 (es)
BR (1) BRPI0810172A2 (es)
CA (1) CA2683443A1 (es)
CO (1) CO6231052A2 (es)
CR (1) CR11058A (es)
DK (1) DK2147096T3 (es)
EC (1) ECSP099735A (es)
ES (1) ES2537328T3 (es)
GT (1) GT200900268A (es)
HN (1) HN2009002098A (es)
IL (2) IL201173A0 (es)
MX (1) MX2009010997A (es)
NI (1) NI200900187A (es)
NZ (2) NZ579985A (es)
PH (1) PH12014501960A1 (es)
PL (1) PL2147096T3 (es)
PT (1) PT2147096E (es)
RU (1) RU2571931C2 (es)
SG (1) SG174077A1 (es)
SI (1) SI2147096T1 (es)
SV (1) SV2009003393A (es)
UA (1) UA101155C2 (es)
WO (1) WO2008127702A2 (es)
ZA (2) ZA200906854B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US7939304B2 (en) * 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
AU2003282724B2 (en) * 2002-10-02 2010-03-04 Catalyst Biosciences, Inc. Methods of generating and screening for proteases with altered specificity
JP5629423B2 (ja) * 2004-04-12 2014-11-19 カタリスト バイオサイエンシーズ， インコーポレイテッド 野生型及び変異型ｍｔ−ｓｐ１による、ｖｅｇｆ及びｖｅｇｆ受容体の切断
JP5219819B2 (ja) * 2005-10-21 2013-06-26 カタリスト・バイオサイエンシーズ・インコーポレイテッド 補体活性化を阻害する修飾プロテアーゼ
EP2423307A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IV polypeptides and use thereof for treatment
SG175602A1 (en) 2006-07-05 2011-11-28 Catalyst Biosciences Inc Protease screening methods and proteases identified thereby
CA2683443A1 (en) * 2007-04-13 2008-10-23 Catalyst Biosciences, Inc. Modified factor vii polypeptides and uses thereof
TWI465247B (zh) * 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
EP2177624A1 (en) * 2008-10-02 2010-04-21 Siemens Healthcare Diagnostics Products GmbH Blood coagulation assays
JP5909180B2 (ja) * 2009-06-25 2016-04-26 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル キメラ第ｖｉｉ因子分子
GB0916578D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
CN103221061A (zh) 2010-10-06 2013-07-24 米迪缪尼有限公司 用于治疗止血障碍的因子ii以及纤维蛋白原
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
WO2012048276A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
CN105755044A (zh) 2011-04-22 2016-07-13 加利福尼亚大学董事会 具有变异衣壳的腺相关病毒病毒体及其使用方法
WO2012149463A1 (en) * 2011-04-29 2012-11-01 The University Of North Carolina At Chapel Hill Chimeric factor vii molecules with enhanced half life and methods of use
EP2554161A1 (en) 2011-08-02 2013-02-06 LFB Biotechnologies Pharmaceutical composition comprising factor VII encapsulated in micelles
CN104271150A (zh) * 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 嵌合因子viii多肽及其用途
MY190257A (en) 2012-04-16 2022-04-11 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
WO2013177584A2 (en) * 2012-05-25 2013-11-28 The Children's Hospital Of Philadelphia FVIIa VARIANTS EXHIBITING ALTERED INTERACTION WITH ENDOTHELIAL PROTEIN C RECEPTOR (EPCR) AND METHODS OF USE THEREOF FOR MODULATING HEMOSTASIS
US8986991B2 (en) * 2012-07-03 2015-03-24 Expression Therapeutics, Llc High yield suspension cell line, system and method for making same
WO2014018120A1 (en) 2012-07-25 2014-01-30 Catalyst Biosciences, Inc. Modified factor x polypeptides and uses thereof
CN104661685A (zh) 2012-10-15 2015-05-27 诺和诺德保健Ag（股份有限公司） 因子vii缀合物
BR112015021866A2 (pt) 2013-03-15 2017-08-29 Bayer Healthcare Llc Domínios de gla como agentes direcionadores
EP3003391B1 (en) 2013-05-31 2021-09-22 The Regents of The University of California Adeno-associated virus variants and methods of use thereof
CN103397009B (zh) * 2013-08-16 2015-06-03 安源生物科技(上海)有限公司 改良型人凝血因子FVII-Fc融合蛋白及其制备方法与用途
CA2927756A1 (en) 2013-10-15 2015-04-23 Novo Nordisk Health Care Ag Coagulation factor vii polypeptides
WO2015073913A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
EP3800191B1 (en) 2014-03-17 2025-08-20 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
EA202190813A1 (ru) * 2014-05-26 2021-12-31 Академиш Зикенхёйс Лейден Прогемостатические белки для лечения кровотечений
EP3198006B1 (en) 2014-09-26 2021-03-24 Terumo BCT, Inc. Scheduled feed
US11021519B2 (en) 2015-03-02 2021-06-01 Adverum Biotechnologies, Inc. Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
JP6836999B2 (ja) 2015-03-24 2021-03-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ アデノ随伴ウイルス変異体及びその使用方法
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
AU2017302013B2 (en) 2016-07-29 2022-05-26 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
CA3040179A1 (en) 2016-10-19 2018-04-26 Adverum Biotechnologies, Inc. Modified aav capsids and uses thereof
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
JP2020519272A (ja) * 2017-05-09 2020-07-02 エモリー ユニバーシティー 凝固因子変異体及びその使用
WO2018222503A1 (en) * 2017-05-31 2018-12-06 The Regents Of The University Of California Adeno-associated virus with variant capsid and methods of use thereof
CA3053154A1 (en) 2017-06-30 2019-01-03 The Regents Of The University Of California Adeno-associated virus virions with variant capsids and methods of use thereof
JP2020534788A (ja) 2017-08-28 2020-12-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アデノ随伴ウイルスカプシド変異体及びその使用方法
EP3679129A1 (en) 2017-09-05 2020-07-15 GLAdiator Biosciences, Inc. A method of intracellular delivery
PL3793588T3 (pl) 2018-05-18 2025-09-01 Bioverativ Therapeutics Inc. Sposoby leczenia hemofilii a
WO2020028886A1 (en) * 2018-08-03 2020-02-06 Duke University Protein c-factor vii chimeras
EP3833381B1 (en) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration
EP4314244B1 (en) 2021-03-23 2025-07-23 Terumo BCT, Inc. Cell capture and expansion
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device
EP4704876A2 (en) * 2023-05-04 2026-03-11 The Cleveland Clinic Foundation Human factor vii deletion constructs for treating cancer

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
DK323587D0 (da) 1987-06-25 1987-06-25 Novo Industri As Protein
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5033352A (en) 1989-01-19 1991-07-23 Yamaha Corporation Electronic musical instrument with frequency modulation
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
ATE180834T1 (de) * 1990-01-29 1999-06-15 Zymogenetics Inc Antikoagulierende proteine
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US20040087498A1 (en) * 1991-02-28 2004-05-06 Novo Nordisk Health Care Ag Modified factor VII
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6344596B1 (en) 1997-02-14 2002-02-05 American Red Cross Expression of active human factor IX in mammary tissue and of milk non human transgenic mammals
US20050032690A1 (en) * 1997-09-10 2005-02-10 Rojkjaer Lisa Payne Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia
US6693075B1 (en) 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) * 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
CA2323638A1 (en) 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
DE19937219A1 (de) 1999-08-06 2001-02-08 Aventis Behring Gmbh Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Ionenaustauscherchromatographie
WO2001032711A2 (en) 1999-10-21 2001-05-10 Board Of Trustees Of The University Of Arkansas Adeno-associated virus aav rep78 major regulatory protein, mutants thereof and uses thereof
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
CA2739933A1 (en) * 2000-02-11 2001-08-16 Bayer Healthcare Llc Factor vii or viia-like molecules
US6905683B2 (en) * 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
JP4455802B2 (ja) 2000-05-03 2010-04-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト第ｖｉｉ凝固因子変異型
JP2004505016A (ja) * 2000-05-10 2004-02-19 ノボ　ノルディスク　アクティーゼルスカブ 第ＶＩＩａ因子及び第ＸＩＩＩ因子を含んで成る医薬組成物
WO2002022776A2 (en) 2000-09-13 2002-03-21 Novo Nordisk A/S Human coagulation factor vii variants
MXPA03001984A (es) * 2000-09-13 2003-08-29 Novo Nordisk Healthcare Ag Variantes de factor vii de coagulacion humano.
BR0114373A (pt) * 2000-10-02 2004-02-17 Novo Nordisk As Célula hospedeira eucariótica, métodos para a produção de fvii e de fviia ou de suas variantes, de uma proteìna dependente de vitamina k e de uma célula hospedeira eucariótica produtora de fvii ou de seu análogo, vetor recombinante, fvii e fviia recombinante ou suas variantes, e, proteìna dependente de vitamina k recombinante
WO2002038162A1 (en) 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
US6800453B2 (en) 2001-01-23 2004-10-05 President And Fellows Of Harvard College Nucleic-acid programmable protein arrays
US20040133930A1 (en) 2002-03-11 2004-07-08 Cooper Julian D. Production of high levels of transgenic factor ix without gene rescue, and its therapeutic uses
US7235638B2 (en) * 2001-03-22 2007-06-26 Novo Nordisk Healthcare A/G Coagulation factor VII derivatives
CZ20032454A3 (en) 2001-03-22 2004-03-17 Novo Nordisk Health Care Ag Coagulation factor vii derivative
AU2002315525A1 (en) * 2001-07-03 2003-01-21 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembrane serine protease 20, the encoded polypeptides and methods based thereon
US7419949B2 (en) * 2001-07-16 2008-09-02 Novo Noridsk Healthcare A/G Single-dose administration of factor VIIa
US6882883B2 (en) * 2001-08-31 2005-04-19 Medtronic, Inc. Implantable medical device (IMD) system configurable to subject a patient to a stress test and to detect myocardial ischemia within the patient
CZ2004427A3 (cs) 2001-09-27 2004-08-18 Novoánordiskáhealthácareáag Polypeptidy lidského koagulačního faktoru VII
US7052868B2 (en) * 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
EP1434857B1 (en) * 2001-10-02 2007-08-01 Novo Nordisk Health Care AG Method for production of recombinant proteins in eukaryote cells
US20030143219A1 (en) * 2001-10-09 2003-07-31 Madison Edwin L Nucleic acid molecules encoding a transmembrane serine protease 25, the encoded polypeptides and methods based thereon
JP3862996B2 (ja) 2001-10-31 2006-12-27 帝人ファイバー株式会社 ポリトリメチレンテレフタレートフィラメント糸およびその製造方法
US6960657B2 (en) * 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US7291587B2 (en) * 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
AU2002357004A1 (en) * 2001-11-20 2003-06-10 Dendreon San Diego Llc Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
AU2002351755A1 (en) * 2001-12-21 2003-07-15 Novo Nordisk A/S Liquid composition of modified factor vii polypeptides
WO2003093465A1 (en) * 2002-04-30 2003-11-13 Maxygen Holdings Ltd. FACTOR VII OR VIIa POLYPEPTIDE VARIANTS
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
DE60336555D1 (de) * 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
AU2003247776A1 (en) * 2002-07-02 2004-01-23 Dendreon Corporation Serine protease 16
US6911323B2 (en) * 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
JP4597678B2 (ja) 2002-09-25 2010-12-15 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト凝固因子ｖｉｉポリペプチド
CA2840692A1 (en) * 2002-09-30 2004-04-08 Bayer Healthcare Llc Fvii or fviia variants having increased clotting activity
AU2003282724B2 (en) * 2002-10-02 2010-03-04 Catalyst Biosciences, Inc. Methods of generating and screening for proteases with altered specificity
CA2519873C (en) * 2003-03-20 2012-12-18 Maxygen Holdings Ltd. Fvii or fviia variants
FI20030413L (fi) 2003-03-20 2004-09-21 Suomen Intech Oy Kaasulaakerointi
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
WO2004087933A2 (en) 2003-03-28 2004-10-14 The Regents Of The University Of California A novel encoding method for 'one-bead one-compound' combinatorial libraries
CA2528239A1 (en) 2003-06-05 2004-12-16 Canadian Blood Services Mutants of the factor vii epidermal growth factor domain
US20060116324A1 (en) * 2003-06-13 2006-06-01 Novo Nordisk Healthcare A/G Novel formulations
RU2373282C2 (ru) 2003-06-19 2009-11-20 Байер Хелткэр Ллк ВАРИАНТЫ ДОМЕНА GLA ФАКТОРА VII ИЛИ VIIa
ES2381110T3 (es) * 2003-09-09 2012-05-23 Novo Nordisk Health Care Ag Polipéptidos de factor VII de coagulación
EP1673453A2 (en) * 2003-10-07 2006-06-28 Novo Nordisk Health Care AG Hybrid molecules having factor vii/viia activity
US20070072271A1 (en) * 2004-01-07 2007-03-29 Novo Nordisk Healthcare A/G Method for the production of recombinant proteins
JP2007522805A (ja) 2004-02-03 2007-08-16 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 新規化合物
JP5629423B2 (ja) * 2004-04-12 2014-11-19 カタリスト バイオサイエンシーズ， インコーポレイテッド 野生型及び変異型ｍｔ−ｓｐ１による、ｖｅｇｆ及びｖｅｇｆ受容体の切断
EP1761630A2 (en) * 2004-06-21 2007-03-14 Novo Nordisk Health Care AG Glycosylation-disrupted factor vii variants
WO2006014253A2 (en) * 2004-07-02 2006-02-09 Genentech, Inc. Factor viia variants
WO2006114105A2 (en) * 2005-04-26 2006-11-02 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
JP5690047B2 (ja) * 2005-09-14 2015-03-25 ノボ ノルディスク ヘルス ケア アーゲー ヒト凝固第ｖｉｉ因子ポリペプチド
EP1929005A1 (en) * 2005-09-21 2008-06-11 Novo Nordisk Health Care AG Human coagulation factor vii polypeptides
JP5219819B2 (ja) * 2005-10-21 2013-06-26 カタリスト・バイオサイエンシーズ・インコーポレイテッド 補体活性化を阻害する修飾プロテアーゼ
EP2423307A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IV polypeptides and use thereof for treatment
SG175602A1 (en) * 2006-07-05 2011-11-28 Catalyst Biosciences Inc Protease screening methods and proteases identified thereby
CA2683443A1 (en) * 2007-04-13 2008-10-23 Catalyst Biosciences, Inc. Modified factor vii polypeptides and uses thereof
TWI465247B (zh) * 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
JP5909180B2 (ja) * 2009-06-25 2016-04-26 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル キメラ第ｖｉｉ因子分子
TWI557135B (zh) * 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
WO2014018120A1 (en) * 2012-07-25 2014-01-30 Catalyst Biosciences, Inc. Modified factor x polypeptides and uses thereof

Also Published As

Publication number Publication date
JP2014042523A (ja) 2014-03-13
CN101743309A (zh) 2010-06-16
UA101155C2 (ru) 2013-03-11
GT200900268A (es) 2015-03-25
JP2010523150A (ja) 2010-07-15
PH12014501960A1 (en) 2015-10-19
PT2147096E (pt) 2015-07-21
KR20150067772A (ko) 2015-06-18
US20100166729A9 (en) 2010-07-01
NZ593611A (en) 2012-06-29
JP2016155836A (ja) 2016-09-01
SI2147096T1 (sl) 2015-07-31
IL201173A0 (en) 2011-08-01
AU2008239586B2 (en) 2013-09-26
ZA201109181B (en) 2012-08-29
CN103451172A (zh) 2013-12-18
HN2009002098A (es) 2012-03-12
EP2481797A1 (en) 2012-08-01
SV2009003393A (es) 2010-04-30
US20090098103A1 (en) 2009-04-16
WO2008127702A3 (en) 2009-03-19
RU2571931C2 (ru) 2015-12-27
EP2147096A2 (en) 2010-01-27
KR20100016462A (ko) 2010-02-12
BRPI0810172A2 (pt) 2014-10-14
AU2008239586A1 (en) 2008-10-23
DK2147096T3 (da) 2015-06-15
NI200900187A (es) 2010-10-11
HK1134520A1 (en) 2010-04-30
CN101743309B (zh) 2014-01-29
EP2147096B1 (en) 2015-03-25
CA2683443A1 (en) 2008-10-23
CO6231052A2 (es) 2010-12-20
IL218776A0 (en) 2012-05-31
WO2008127702A2 (en) 2008-10-23
PL2147096T3 (pl) 2015-08-31
ES2537328T3 (es) 2015-06-05
NZ579985A (en) 2012-02-24
SG174077A1 (en) 2011-09-29
ZA200906854B (en) 2012-03-28
RU2009141510A (ru) 2011-05-20
JP5761782B2 (ja) 2015-08-12
MX2009010997A (es) 2009-11-02
CR11058A (es) 2010-02-09

Similar Documents

Publication Publication Date Title
ECSP099735A (es) Polipeptidos de factor vii modificados y usos de los mismos
CO6331368A2 (es) Factores modificados de polipeptidos vii (fvii)
ECSP088508A (es) Antagonistas de neuropilina
MY162576A (en) Modified factor ix polypeptides and uses thereof
CY1122554T1 (el) Συνδυασμοι φαρμακων
ECSP067046A (es) Indazoles sustituidos, composiciones que los contienen, procedimiento de preparación y su uso
CR20200101A (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y métodos de uso de anticuerpos anti-cd39
GT200600240A (es) Anticuerpos monoclonales anti-trkb y usos de los mismos
ECSP099619A (es) Anticuerpos anti-robo4 y sus usos
SV2010003704A (es) Polipeptidos modificados del factor ix y usos de los mismos
CL2015002941A1 (es) Usos terapéuticos de empaglifozina
SV2010003559A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
BRPI0809583A2 (pt) polipeptídeos fgf-21 modificados e seus usos
GT201200023A (es) Polipéptidos del factor ix modificados y usos de los mismos
NI201000044A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
HN2008000738A (es) Compuestos para la inhibicion de enzimas
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
CR20190480A (es) Uso de antagonistas de klk5 para el tratamiento de una enfermedad
NI201000015A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
UY29249A1 (es) Agentes citotóxicos que comprenden taxanos nuevos
UY29250A1 (es) Agentes citotóxicos que comprenden nuevos taxanos modificados en c-2.-
GT200600106A (es) Agentes endoparasiticidas
DK1713438T3 (da) Medicinsk sæbe
CR9486A (es) Composiciones y metodos para el diagnostico y tratamiento del tumor
Berger Redefining the domains of decision making by physician and patient